Pulmonary Hypertension in TAVR
boards, and all the data are fully available to the enrolling centers. All patients were evaluated for TAVR by the local Heart Team that included a clinical cardiologist, an interventional cardiologist, a cardiac surgeon, and a cardiac anesthesiologist. The evaluation of the Heart Team led to the indication for TAVR after careful assessment of all the clinical/anatomic conditions determining a higherrisk of mortality/morbidity after surgery. All patients scheduled for TAVR and who gave written consent for the procedure and registry were enrolled. There were no exclusion criteria for inclusion in this registry except for completeness of echocardiographic data. However, for the present study, patients with a failed aortic bioprosthesis have been excluded from the analysis and evaluated in a different publication. 10 Patients with prior mitral valve surgery have been excluded from the current analysis as well. Follow-up was scheduled in all patients at 1, 6, and 12 months, and then yearly. Patients were followed up by means of outpatient clinics and regular contact with general practitioners.
Device and Procedure
The CoreValve prosthesis and the procedure have been described elsewhere. [1] [2] [3] [4] After the procedure, most patients were managed in an Intensive Care Unit or Coronary Care Unit for at least a day, and a temporary pacemaker was left in place for at least 48 hours. All patients received acetylsalicylic acid (at least 100 mg before the procedure and lifelong) and clopidogrel (300 mg bolus plus 75 mg daily for 3-6 months unless prolonged adminisctration was required for previous coronary intervention with drugeluting stents). During the intervention, unfractioned heparin was administered to achieve an activated clotting time of 200 to 250 seconds for the duration of the procedure. In the case of significant concomitant coronary disease, percutaneous intervention was performed before TAVR.
Study Schedule and Definitions
Transthoracic echocardiography was performed before TAVR, within 3 days after TAVR, and at 1, 6, and 12 months by a senior cardiologist. Echocardiographic parameters have been determined and categorized according to the American Society of Echocardiography, European Association of Echocardiography, and the Canadian Society of Echocardiography recommendations and consensus documents. [10] [11] [12] Patients were divided into 3 groups according to the absence of PH (systolic pulmonary artery pressure [sPAP], <40 mm Hg: group 1), moderate PH (sPAP, 40-60 mm Hg: group 2), or severe PH (sPAP, >60 mm Hg: group 3) before the procedure. sPAP was estimated by transthoracic echocardiography, based on the simplified Bernoulli equation describing the relationship between the velocity and the peak pressure gradient of tricuspid regurgitation: (peak pressure gradient)=4×(tricuspid regurgitation velocity); sPAP can be estimated from this equation, taking into account right atrial pressure, based on inferior vena cava diameter and respiratory variation: sPAP=tricuspid regurgitation peak pressure gradient+estimated right atrial pressure. A complete echocardiographic evaluation has been done before, immediately after the procedure, at discharge, and then at 1, 6, and 12 months.
Frailty has been defined according to Winograd et al. 13 Oneyear clinical follow-up, or a medical record reporting a fatality, was available in all patients, whereas echocardiographic follow-up was available in all patients who reached 1-year follow-up (797 patients, as per 193 fatalities overall). Clinical end points (overall mortality, cardiac mortality, New York Heart Association (NYHA) class, and rate of hospitalization for heart failure) were assessed at 1 month and 1 year after the procedure and defined according to VARC-2 definitions. 14
Statistical Analysis
Continuous variables with normal distribution are presented as mean±SDs and compared using a F test through generalized linear model. Variables not following a normal distribution were compared with a Mann-Whitney U test for comparisons between groups. Categorical variables are presented as counts and percentages and were compared using χ 2 or Fisher exact tests, as appropriate. The presence of a trend accounting for the ordinal nature of the 3 groups has been tested, as appropriate. The cumulative incidences of clinical events at follow-up were assessed with the Kaplan-Meier method and log-rank test.
Three different models of Cox stepwise multivariate analyses for all-cause mortality have been performed, all of them including all the baseline variables correlating with sPAP at a P<0.1 on univariate analysis (hypertension, chronic obstructive pulmonary disease, frailty, moderate PH, severe PH, left ventricular ejection fraction [LVEF] <30%, previous balloon valvuloplasty, bypass graft surgery, severe mitral regurgitation [MR]):
1. The first and more comprehensive model considered the absence of PH as a reference group to look at the hazard ratio (HR) of moderate and severe PH. 2. The second model included 1-month severe PH (but not the baseline PH severity to avoid the collinearity), to investigate the possible association of 1-month PH with mortality. 3. The third model included the decrease of the sPAP to assess a possible association with mortality and was obviously restricted to baseline moderate and severe PH baseline. Results are presented as HRs with 95% confidence interval. The validity of the proportionality assumption was verified for all covariates by a visual examination of the log (minus log) curves and a test based on Schoenfeld residuals. We then validated internally the model with percentile bootstrap (10 000 samples), reporting bootstrapped median and 95% confidence intervals for the coefficients. This is in keeping with established recommendations and practice for cardiovascular observational research. 15 All probability values reported are 2-sided, and a P<0.05 was considered to be significant. All data were
WHAT IS KNOWN
• Severe pulmonary hypertension (PH) is relatively common among patients with severe aortic stenosis.
• Severe PH is a weak predictor of mortality in the setting of transcatheter aortic valve replacement.
• In some cases after transcatheter aortic valve replacement, PH improves significantly.
WHAT THE STUDY ADDS
• Improvement in PH can be observed acutely, but after 1 month it does not improve further.
• The persistence of severe PH at 1 month after TAVR is a stronger predictor of mortality than baseline PH.
• The absence of atrial fibrillation, a functional cause of mitral regurgitation, and the absence of severely depressed left ventricular ejection fraction are predictors of an improvement of at least 15 mm Hg in pulmonary artery pressure.
• A decrease of the pulmonary artery pressure of at least 15 mm Hg does not independently predict mortality.
• The benefit of transcatheter aortic valve replacement in terms of quality of life is substantial in patients with and without a reduction of systolic pulmonary artery pressure at early follow-up. Pulmonary Hypertension in TAVR processed using the Statistical Package for Social Sciences, version 20 (SPSS, Chicago, IL).
Results
Baseline and procedural features of the study population according to baseline PH status are shown in Tables 1 and  2 . Severe PH at the time of the procedure was present in 218 patients (ie, 22% of the population). Patients with severe PH more often were in a worse clinical condition as demonstrated by a higher mean LogEuroscore, a more frequent NYHA class ≥3 at presentation, and a numerically higher incidence of clinically relevant frailty. Mean LVEF tended to be lower in patients with severe PH, whereas the rate of patients with severely reduced LVEF (<30%) was significantly higher. Likewise, the incidence of atrial fibrillation was significantly higher among patients with severe PH. The rate of severely depressed right ventricle function was similar across the groups. Of note, no significant differences were observed across groups with regard to procedural data, meaning that a severe PH did not affect the safety of the procedure and its efficacy.
Analysis of Mortality
Overall Mortality At 1 month, conceivably as a consequence of a low-rate of events, overall mortality did not significantly differ across the 3 groups. (Table 3 ; Figure 1 ). Group 3 had a significantly higher-rate of patients in NYHA class 3 to 4 and of hospitalization for heart failure (Table 3) Percentile bootstrap (10 000 samples), reporting bootstrapped median and 95% confidence intervals for the coefficients, internally validated the models, and consistency between HRs can be checked in Table I in the Data Supplement.
Cardiac Mortality
At 1 month, cardiac mortality did not differ across the three groups (Figure 2 ). At 1 year, when compared with patients in group 1, patients in group 2 and in group 3 had a higher 
Noncardiac Mortality
Noncardiac mortality did not differ across the 3 groups at 1 month and at 1 year.
Rate of Hospitalization for Heart Failure and NYHA Functional Class
At 30 days, the rate of hospitalization for heart failure was significantly higher (7% versus 3% and 3%) compared with groups 1, 2 and 3 and the percentage of patients with NYHA class 3 to 4 significantly higher (26% versus 12% and 10%) among patients in group 3 (Table 3) . At 1 year, the rate of hospitalization for heart failure was still higher in group 3 (16% versus 13% and 9%); on the contrary, the rate of NYHA class 3 to 4, although numerically higher in group 3, did not reach statistical significance (Table 3 ).
Pulmonary Pressure After TAVR
After 1 month, the systolic pulmonary pressure decreased at least 15 mm Hg in 32% and 35% of the patients in groups 2 and 3. At 1 year, no further decreases were observed among survivors.
Features of patients in groups 2 and 3 who experienced either an improved (≥15 mm Hg of the systolic pulmonary Table 4 .
Notably, regardless of the severity of PH at baseline, patients with a reduced PH at 1 month after TAVR had a significantly lower-rate of atrial fibrillation, severe MR, and severely depressed LVEF (<30%).
Consistently, according to Cox-regression analysis, the absence of atrial fibrillation (HR, 1.9 [1.4-2.9]; P=0.003), a functional cause of MR (HR, 2.1 [1.8-3.1]; P=0.005) , and the absence of severely depressed LVEF (HR, 1.8 [1.3-2.6]) were predictors of an improved PH of at least 15 mm Hg.
Discussion
Main findings of this large multicenter registry are:
1. the persistence of severe PH at 1 month after TAVR is a stronger predictor than baseline severe PH, 2. both moderate and severe PH can significantly improve after TAVR, 3. such an improvement, although associated with a consistent improvement in the NYHA class does not independently predict mortality.
The mechanism underlining the relationship between aortic stenosis and PH lies on the increased rigidity of the LV: the progressive diastolic dysfunction caused by the hypertrophy of the myocardium leads to an increased filling pressure in the LV and thus in the left atrium that eventually retrogradely involves the pulmonary circulation. 16 The coexistence of MR makes this mechanism more complex as the stiffness of the myocardium facilitates the MR; on the other hand, the MR itself may lead to an increased filling pressure. 17 The prognostic impact of PH in patients treated for aortic stenosis is well known in the setting of surgical aortic valve replacement: patients showing a baseline severe PH have a higher-risk of long-term mortality. 18, 19 Few previous publication investigated whether this condition was associated with higher mortality even in patients undergoing TAVR, and there is consistency between the present registry and the published literature about the weak association of severe baseline PH with mortality. [1] [2] [3] [4] [5] Differently from previously published literature, in particular, from the substudy of the France-2 registry, 5 we could not find any significant survival benefit of the improvement in 8 reported that postimplant sPAP was statistically associated with overall survival both as a continuous and an ordinal measure. In the France-2 registry, a decrease of at least 20 mm Hg in the sPAP was considered an ordinal measure, whereas we considered 15 mm Hg; this could partially explain this discrepancy, as a larger improvement may possibly be associated with a larger benefit.
However, it is more difficult to understand how the improved sPAP as a continuous variable could have been associated with improved mortality. Of note, among >3000 patients included in the French registry, only those with a reported sPAP at baseline were included (2435 patients) and, among them, ≈25% had an echo follow-up at 1 year post procedure, whereas the median follow-up was 178 days. This obviously poses a significant risk of unpowered analysis and of selection bias.
In our national registry, the improvement of ≥15 mm Hg in the sPAP after TAVR was consistent across groups and associated at follow-up with an improved vital status as confirmed by the strongly reduced rate of patients in NYHA class 3 to 4 in all groups, and the low-rate of hospitalization among survivors.
The main contribution of the present study to current knowledge is the strong association of persistent severe PH after TAVR with mortality. This association is far stronger than that of baseline severe PH with mortality and conceivably reflects the presence of cases in which the improved hemodynamic, subsequent to a restored normal aortic valve function, is not able to ameliorate the pulmonary circulation performance. Thus, we can hypothesize that when the modifications of the pulmonary circulation reach an advanced stage, they may become irreversible despite the intervention on the aortic valve and the immediate reduction in the filling pressure of the left-side heart. Our data showed that the absence of atrial fibrillation, a functional cause of MR, and the absence of severely depressed LVEF predicted the improvement of PH.
Additional studies are needed to confirm or deny these findings. However, regardless of the possible irreversibility of the PH, the impact on the quality of life is substantial in the majority of patients, meaning that even if a severe PH persists, patients can experience a significantly improved global status. A possible explanation for such an improvement conceivably relies on the multifaceted nature of the physical performance; in other words, the restoration of a more physiological hemodynamic of the left heart could be sufficient to determine a better global status even in the presence of an unchanged pulmonary pressure.
Limitations
The evaluation of pulmonary pressure by means of echocardiography is indirect (ie, derived by the sum of tricuspid regurgitation peak pressure gradient+estimated right atrial pressure). The gold standard is the invasive measurement done by means of right-heart catheterization; however, in largescale multicenter registries such an invasive procedure would probably be logistically hard to perform in a high percentage of patients.
As obvious in the nature of a registry, the lack of any randomization and differences in local experience could have added bias to our results. Our data have been collected in a nationwide registry and extensively monitored on sites. The possibility of a selection bias is unlikely, as every patient treated by means of CoreValve Revalving System-TAVR has been enrolled, provided that informed consent was obtained.
Conclusions
The persistence of a severe PH after TAVR is a stronger predictor of 1-year mortality than a baseline severe PH. An improved PH is not associated with improved survival. Notably, the benefit of TAVR in terms of quality of life is substantial in patients with and without a reduction of sPAP at early follow-up.
